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Background:  We sought to assess outcomes and risk stratification tools in a large population of patients with hypertrophic 
cardiomyopathy.
methods:  178 consecutive patients (71 female, age 48 ± 16 yrs; 109 with outflow tract obstruction) with hypertrophic cardiomyopathy were 
included and followed. Outcome was assessed and overall and event-free survival was determined.
results:  Overall event-free survival with events defined as implantation of an implantable cardioverter defibrillator (ICD), sudden death 
or unexplained syncope, new onset atrial fibrillation, septal myectomy or alcohol ablation were 90±2% , 82±3% and 69±4% after 1,2 and 4 
years respectively with significantly higher event rates for patients with outflow tract obstruction (84±3%, 75±4% and 57±5% after 1,2 and 
4 years respectively; p < 0.001). ICDs were implanted in 26 patients, 3 (12%) of which were sudden cardiac death (SCD) survivors. In pts 
that received an ICD, 2 or more risk factors for SCD were present in 42.3% and the recently introduced HCM Risk-SCD score was ≥ 6% in 
69.2%. In 6 (23%) patients adequate therapy was delivered by the device (ATP in 4 patients, shock in 2 patients). 2 or more risk factors for 
SCD were found in 38.5% of patients with arrythmogenic events (sudden death survivor or adequate ICD therapy) and 15.2% of patients 
without arrythmogenic events (p =0.05). The HCM Risk-SCD score was significantly higher in patients with arrythmogenic events (11.4% vs 
5.2%; p < 0.001). However, a HCM Risk-SCD score ≥ 6% was found in 29.1% of patients without arrythmogenic events and a score < 6% 
in 46.1% of patients with arrythmogenic events (p=0.07).
conclusion:  Patients with hypertrophic cardiomyopathy have high event rates, especially when outflow tract obstruction is present. While 
the presence of two or more risk factors and a high HCM Risk-SCD score identify patients at risk for arrhythmogenic events, their sensitivity 
and specificity in clinical practice is suboptimal.
